Correspondence 0001213900-23-025880 from PURPLE BIOTECH LTD. (PPBT)
PURPLE BIOTECH LTD.
Date: April 3, 2023 · CIK: 0001614744 · Accession: 0001213900-23-025880
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-270769
Letter
Purple Biotech Ltd.
4 Oppenheimer Street
Science Park
Rehovot 7670104, Israel
April 3, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street N.E.
Washington, D.C. 20549
Attention: Cindy Polynice
Re:
PURPLE BIOTECH LTD.
Registration Statement on Form F-3
Filed March 23, 2023
File No. 333-270769
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Purple Biotech Ltd. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form F-3 (File No. 333-270769) (the “Registration Statement”) be accelerated by the Securities and Exchange Commission to 4:30 p.m., Eastern Time on April 5, 2023, or as soon thereafter as practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to the Company’s counsel, Haynes and Boone, LLP, by calling Jayun Koo at (212) 659-7300, and that such effectiveness also be confirmed in writing.
Very truly yours,
Purple Biotech Ltd.
Show Raw Text
CORRESP
1
filename1.htm
Purple Biotech Ltd.
4 Oppenheimer Street
Science Park
Rehovot 7670104, Israel
April 3, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street N.E.
Washington, D.C. 20549
Attention: Cindy Polynice
Re:
PURPLE BIOTECH LTD.
Registration Statement on Form F-3
Filed March 23, 2023
File No. 333-270769
Ladies and Gentlemen:
Pursuant to Rule 461 of the
General Rules and Regulations under the Securities Act of 1933, as amended, Purple Biotech
Ltd. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement
on Form F-3 (File No. 333-270769) (the “Registration Statement”) be accelerated by the Securities
and Exchange Commission to 4:30 p.m., Eastern Time on April 5, 2023, or as soon thereafter as practicable.
The undersigned respectfully
requests that it be notified of the effectiveness of the Registration Statement by telephone call to the Company’s counsel, Haynes
and Boone, LLP, by calling Jayun Koo at (212) 659-7300, and that such effectiveness also be confirmed
in writing.
Very truly yours,
Purple Biotech Ltd.
By:
/s/
Isaac Israel
Isaac Israel
Acting Chief Executive Officer
cc:
Rick A. Werner, Esq., Haynes and Boone, LLP
Jayun Koo, Esq., Haynes and Boone, LLP